Molecular Tumor Board - A Registry of the East German Hematology and Oncology Study Group.

Molecular Tumor Board - A Registry of the East German Hematology and Oncology Study Group. - MTBreg-OSHO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032977

Enrollment

250

Registered

2023-11-02

Start date

2023-11-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic or oncologic diseases

Interventions

Group 1: Patients with hematological or oncological disease

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Signed consent form - Hematological or oncological disease - Present question regarding molecular diagnostics or therapy

Exclusion criteria

Exclusion criteria: No questioning in the context of the molecular tumor board

Design outcomes

Primary

Measure	Time frame
Generation of a molecular map in hematology and oncology	—

Secondary

Measure	Time frame
- Number of patients with hemato-oncologic disease and molecular issues. - Consideration of the collected registry data both longitudinally and transversally - Outcome of the patients in dependence of the collected diseases and their specific characteristics, especially the molecular biological characteristics and the therapy sequences - Outcome of patients depending on the molecular biological characteristics of their hematologic or oncologic disease - Outcome as a function of the quality of life assessed against the background of the course of the disease - Analysis of the MTB recommendations and their adherence - Influence of patient-related factors (sociodemographics) on the primary and the mentioned secondary endpoints	—

Measure

Time frame

- Number of patients with hemato-oncologic disease and molecular issues. - Consideration of the collected registry data both longitudinally and transversally - Outcome of the patients in dependence of the collected diseases and their specific characteristics, especially the molecular biological characteristics and the therapy sequences - Outcome of patients depending on the molecular biological characteristics of their hematologic or oncologic disease - Outcome as a function of the quality of life assessed against the background of the course of the disease - Analysis of the MTB recommendations and their adherence - Influence of patient-related factors (sociodemographics) on the primary and the mentioned secondary endpoints

—

Countries

Germany

Contacts

Public ContactSusann Schulze

Krukenberg-Krebszentrum Halle (KKH), Universitätsmedizin Halle (Saale)

susann.schulze2@uk-halle.de+493455572001

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 27, 2026